Skip to content
10-Q

Quarterly Report

Revolution Medicines, Inc. RVMD RVMDW

0001193125-26-208969

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 212.6M sh
Shares Diluted Q1 2026 · Mar 31, 2026 198.1M sh
Shares Diluted Q1 2026 · Mar 31, 2025 188.15M sh
Capex Q1 2026 · Mar 31, 2026 $1.54M
Capex Q1 2026 · Mar 31, 2025 $3.27M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$354.17M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$194.44M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $440.94M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $383.75M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $333.55M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.5B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.63B
Stockholders Equity Q1 2026 · Mar 31, 2025 $2.08B
Stockholders Equity Q1 2026 · Dec 31, 2024 $2.27B
Current Liabilities Q1 2026 · Mar 31, 2026 $289.6M
Current Liabilities Q1 2026 · Dec 31, 2025 $290.42M
Total Liabilities Q1 2026 · Mar 31, 2026 $753.82M
Total Liabilities Q1 2026 · Dec 31, 2025 $723.21M
Current Assets Q1 2026 · Mar 31, 2026 $1.97B
Current Assets Q1 2026 · Dec 31, 2025 $2.08B
Total Assets Q1 2026 · Mar 31, 2026 $2.25B
Total Assets Q1 2026 · Dec 31, 2025 $2.35B
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.29
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.13
Eps Basic Q1 2026 · Mar 31, 2026 −$2.29
Eps Basic Q1 2026 · Mar 31, 2025 −$1.13
Sga Expense Q1 2026 · Mar 31, 2026 $101.25M
Sga Expense Q1 2026 · Mar 31, 2025 $35.01M
Rd Expense Q1 2026 · Mar 31, 2026 $343.97M
Rd Expense Q1 2026 · Mar 31, 2025 $205.75M
Net Income Q1 2026 · Mar 31, 2026 −$453.82M
Net Income Q1 2026 · Mar 31, 2025 −$213.42M
Operating Income Q1 2026 · Mar 31, 2026 −$445.22M
Operating Income Q1 2026 · Mar 31, 2025 −$240.76M